Cargando…
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
BACKGROUND: Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focu...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021110/ https://www.ncbi.nlm.nih.gov/pubmed/27113479 http://dx.doi.org/10.1002/mds.26613 |
_version_ | 1782453301779890176 |
---|---|
author | Kang, Un Jung Goldman, Jennifer G. Alcalay, Roy N. Xie, Tao Tuite, Paul Henchcliffe, Claire Hogarth, Penelope Amara, Amy W. Frank, Samuel Rudolph, Alice Casaceli, Cynthia Andrews, Howard Gwinn, Katrina Sutherland, Margaret Kopil, Catherine Vincent, Lona Frasier, Mark |
author_facet | Kang, Un Jung Goldman, Jennifer G. Alcalay, Roy N. Xie, Tao Tuite, Paul Henchcliffe, Claire Hogarth, Penelope Amara, Amy W. Frank, Samuel Rudolph, Alice Casaceli, Cynthia Andrews, Howard Gwinn, Katrina Sutherland, Margaret Kopil, Catherine Vincent, Lona Frasier, Mark |
author_sort | Kang, Un Jung |
collection | PubMed |
description | BACKGROUND: Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well‐characterized, clinically typical, moderate to advanced PD cohorts is critically needed. METHODS: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross‐sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. RESULTS: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. CONCLUSION: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society |
format | Online Article Text |
id | pubmed-5021110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50211102016-09-23 The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort Kang, Un Jung Goldman, Jennifer G. Alcalay, Roy N. Xie, Tao Tuite, Paul Henchcliffe, Claire Hogarth, Penelope Amara, Amy W. Frank, Samuel Rudolph, Alice Casaceli, Cynthia Andrews, Howard Gwinn, Katrina Sutherland, Margaret Kopil, Catherine Vincent, Lona Frasier, Mark Mov Disord Research Articles BACKGROUND: Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well‐characterized, clinically typical, moderate to advanced PD cohorts is critically needed. METHODS: BioFIND (Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease) is a cross‐sectional, multicenter biomarker study that established a repository of clinical data, blood, DNA, RNA, CSF, saliva, and urine samples from 118 moderate to advanced PD and 88 healthy control subjects. Inclusion criteria were designed to maximize diagnostic specificity by selecting participants with clinically typical PD symptoms, and clinical data and biospecimen collection utilized standardized procedures to minimize variability across sites. RESULTS: We present the study methodology and data on the cohort's clinical characteristics. Motor scores and biospecimen samples including plasma are available for practically defined off and on states and thus enable testing the effects of PD medications on biomarkers. Other biospecimens are available from off state PD assessments and from controls. CONCLUSION: Our cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society John Wiley and Sons Inc. 2016-04-26 2016-06 /pmc/articles/PMC5021110/ /pubmed/27113479 http://dx.doi.org/10.1002/mds.26613 Text en © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Kang, Un Jung Goldman, Jennifer G. Alcalay, Roy N. Xie, Tao Tuite, Paul Henchcliffe, Claire Hogarth, Penelope Amara, Amy W. Frank, Samuel Rudolph, Alice Casaceli, Cynthia Andrews, Howard Gwinn, Katrina Sutherland, Margaret Kopil, Catherine Vincent, Lona Frasier, Mark The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title_full | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title_fullStr | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title_full_unstemmed | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title_short | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort |
title_sort | biofind study: characteristics of a clinically typical parkinson's disease biomarker cohort |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021110/ https://www.ncbi.nlm.nih.gov/pubmed/27113479 http://dx.doi.org/10.1002/mds.26613 |
work_keys_str_mv | AT kangunjung thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT goldmanjenniferg thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT alcalayroyn thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT xietao thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT tuitepaul thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT henchcliffeclaire thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT hogarthpenelope thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT amaraamyw thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT franksamuel thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT rudolphalice thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT casacelicynthia thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT andrewshoward thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT gwinnkatrina thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT sutherlandmargaret thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT kopilcatherine thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT vincentlona thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT frasiermark thebiofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT kangunjung biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT goldmanjenniferg biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT alcalayroyn biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT xietao biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT tuitepaul biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT henchcliffeclaire biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT hogarthpenelope biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT amaraamyw biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT franksamuel biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT rudolphalice biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT casacelicynthia biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT andrewshoward biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT gwinnkatrina biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT sutherlandmargaret biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT kopilcatherine biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT vincentlona biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort AT frasiermark biofindstudycharacteristicsofaclinicallytypicalparkinsonsdiseasebiomarkercohort |